Volumetric evaluation of an alternative bladder point in brachytherapy for locally advanced cervical cancer.
OBJECTIVE
To evaluate an alternative dose point, so-called ALG (for Alain Gerbaulet), for the bladder in comparison to the International Commission on Radiation Units and Measurements (ICRU) point and D2cm(3) (minimal dose to maximally exposed 2 cm(3)) in a large cohort of patients with locally advanced cervical cancer treated with external beam radiotherapy followed by image-guided pulsed dose rate brachytherapy.


METHODS
For each patient, the ALG point was constructed 1.5 cm above the ICRU bladder, parallel to the tandem (coronal and sagittal planes). The dosimetric data from 162 patients were reviewed.


RESULTS
Average doses to ALG and bladder points were 19.40 Gy ± 7.93 and 17.14 ± 8.70, respectively (p=0.01). The 2 cm(3) bladder dose averaged 24.40 ± 6.77 Gy. Ratios between D2cm(3) and dose points were 1.37 ± 0.46 and 1.68 ± 0.74 (p<0.001) for ALG and ICRU points, respectively. Both dose points appeared correlated with D2cm(3) (p<0.001) with coefficients of determination (R(2)) of 0.331 and 0.399 respectively. The estimated dose to the ICRU point of the rectum was 12.77 ± 4.21 and 15.76 ± 5.94 for D2cm(3) (p<0.0001). Both values were significantly correlated (p<0.0001, R(2) = 0.485).


CONCLUSIONS
The ALG point underestimates the D2cm(3), but its mean on a large cohort is closer to D2cm(3) than the dose to ICRU point. However, it shows great variability between cases and the weak strength of its correlation to D2cm(3) indicates that it is not a good surrogate for individual volumetric evaluation of the dose D2cm(3).
Department of Radiation Oncology, Gustave Roussy, 114, rue Edouard Vaillant, 94805, Villejuif Cedex, France, renaud.mazeron@gustaveroussy.fr.
R
R
Mazeron
J
J
Gilmore
J
J
Champoudry
I
I
Dumas
J
J
Helou
P
P
Maroun
F
F
Martinetti
A
A
Gerbaulet
C
C
Haie-Meder
D001918:Brachytherapy / Q000706:statistics & numerical data*; D015897:Comorbidity; D004307:Dose-Response Relationship, Radiation; D005260:Female; D005602:France / Q000453:epidemiology; D006801:Humans; D015994:Incidence; D011832:Radiation Injuries / Q000453:epidemiology* / Q000517:prevention & control*; D011879:Radiotherapy Dosage; D012189:Retrospective Studies; D018570:Risk Assessment; D012307:Risk Factors; D047368:Tumor Burden; D001745:Urinary Bladder Diseases / Q000453:epidemiology* / Q000517:prevention & control*; D002583:Uterine Cervical Neoplasms / Q000453:epidemiology* / Q000532:radiotherapy*